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Abstract
Background: The Luminex bead-based multiplex assay is useful for quantifying immune mediators such as
cytokines and chemokines. Cross-comparisons of reagents for this technique from different suppliers have already
been performed using serum or plasma but rarely with supernatants collected from antigen-stimulated peripheral
blood mononuclear cells (PBMC). Here, we first describe an optimization protocol for cell culture including quantity
of cells and culture duration to obtain reproducible cytokine and chemokine quantifications. Then, we compared
three different Luminex kit suppliers.
Results: Intraclass correlation coefficients (ICCs) for a 2-days stimulation protocol were >0.8 for IFNγ and Perforin.
The specific concentration was maximal after two or five days of stimulation, depending on the analyte, using 0.5
million PBMC per well, a cell quantity that gave the same level of specific cytokine secretion as 1.0 million. In the
second part of the study, Luminex kits from Millipore showed a better working range than Bio-Rad and Ozyme
ones. For tuberculin purified protein derivative (PPD)-stimulated samples, the overall mean pooled coefficients of
variation (CVs) for all donors and all cytokines was 17.2 % for Bio-Rad, 19.4 % for Millipore and 26.7 % for Ozyme.
Although the different kits gave cytokine concentrations that were generally compatible, there were discrepancies
for particular cytokines. Finally, evaluation of precision and reproducibility of a 15-plex Millipore kit using a
“home-made” internal control showed a mean intra-assay CV <13 % and an inter-assay CV <18 % for each
cytokine concentration.
Conclusions: A protocol with a single round of stimulation but with two time points gave the best results for
assaying different cytokines. Millipore kits appear to be slightly more sensitive than those from Bio-Rad and
Ozyme. However, we conclude that the panel of analytes that need to be quantified should be the main
determinant of kit selection. Using an internal control we demonstrated that a 15-plex magnetic Milliplex kit
displayed good precision and reproducibility. Our findings should help optimize assays for evaluating immune
responses during the course of disease or infection, or in response to vaccine or therapy.
Keywords: Luminex, Cytokine, Reproducibility, Precision, Culture supernatant
* Correspondence: christine.lacabaratz@inserm.fr
1INSERM, U955, Equipe 16, Créteil F-94010, France
2Université Paris Est, Faculté de médecine, Créteil F-94010, France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Surenaud et al. BMC Immunology  (2016) 17:44 
DOI 10.1186/s12865-016-0182-8
Background
Cytokines and chemokines are soluble molecules playing
key roles in the innate and adaptive immune responses.
Quantifying these immune mediators has become increas-
ingly important to obtain better descriptions of immune re-
sponses during the course of disease or infections, or to a
vaccine, therapy and intervention; such detailed descrip-
tions allow the identification of correlates of cure or protec-
tion. Various methods can be used to measure cytokines
and chemokines, and enzyme-linked immunosorbent assay
(ELISA) is still the most extensively employed [1]. This
monoplex antibody-based immunoassay has been used for
more than fifty years but can be laborious, sample consum-
ing and expensive when studying profiles of large numbers
of cytokines and chemokines. Therefore, a number of
new technologies allowing simultaneous quantitative
measurements of multiple cytokines and chemokines in
small sample volumes have recently been developed.
These multiplex immunoassay systems can be divided
into two classes: planar assays and suspension micro-
sphere assays [2]. The Multi-array Meso Scale Discov-
ery (MSD) electro-chemiluminescence detection system
(planar immunoassay) and Luminex xMAP technology
(microsphere immunoassay) are considered to be the
two most suitable platforms for biomarker analysis or
quantification [3–5].
The growing use of Luminex technology has led to dif-
ferent kits being made available by several companies,
and we decided to work with this multiplex platform.
The Luminex system allows the analysis of up to 100
analytes in a single well. Relatively small volumes (25–
50 μl) of serum, plasma, other body fluids, or cell culture
supernatant can be assayed for cytokines and chemo-
kines. Extensive data have been published validating the
Luminex platform for detection of multiple analytes, by
comparing this technique with ELISA [6–12]. Cross-
comparisons between reagent suppliers showed variabil-
ity in absolute cytokine concentration results in serum
or plasma [13–15]. Moreover, a study comparing Luminex
kits from three different companies, including World
Health Organization (WHO) cytokine standards in
addition to the standards provided with each kit, revealed
striking differences in results for cytokine concentrations
in serum [16].
There have been few studies comparing different
Luminex kits using supernatants from antigen-stimulated
cell culture, an approach used in vaccine research. One
study compared Luminex kits from three different sup-
pliers for the determination of cytokine levels in whole
blood culture supernatant [17], and two studies compared
cytokine and chemokine levels in supernatants from anti-
gen specific-stimulated peripheral blood mononuclear cells
(PBMC) as tested with different commercial Luminex kits
[18, 19]. These studies revealed differences of performance
(accuracy, recovery, reproducibility) between the suppliers
tested. Defawe and colleagues published a study on
optimization and validation of a Luminex protocol to
assess cytokine and chemokine production by vaccine-
specific cells to allow better characterization of immune
responses [20]. However, the optimization of the “cell cul-
ture step” described in their work could be improved. The
aim of the present study was to optimize a cell culture
protocol (including quantity of cells, culture duration, and
positive control) to obtain reproducible cytokine and
chemokine quantifications by Luminex technology in
antigen-stimulated PBMC supernatants; the second aim
was then to compare the performances of different
Luminex kits.
Results
Reproducibility of the Luminex assay
We first performed an intra-laboratory reproducibility
study with a multiplex assay developed and shared by
the Baylor Institute for Immunology Research (BIIR)
and using polystyrene beads (Table 1). PBMC from six
Human Immunodeficiency virus (HIV)-infected patients
(CD4 count > 500 mm3, viral load < 50 copies/ml) were
cultured without stimulation or with: (i) LIPO-5 HIV-1
vaccine [21], (ii) a mix of five long HIV-1 peptides (LP
mix), (iii) a 15-mers HIV-1 peptide pool and (iv)
Staphylococcal Enterotoxin B (SEB) as a positive control.
Three independent cultures were performed: 1 million
PBMC/well were cultured in triplicate for 2 and 11 days,
and assayed for IFNγ, perforin, IL-5 and IL-17. In the
11 day-cultures (two-step stimulation protocol), high
concentrations and large variations were observed for all
cytokines with SEB and peptide stimulations (Additional
file 1: Figure S1). For example, LP mix induced from
4,810 to 357,392 pg/ml for IFNγ with PBMC from pa-
tient A and from 16 to 5,421 pg/ml for perforin with
PBMC from patient B. By contrast, a short stimulation
period without re-stimulation could lead to more repro-
ducible results (Additional file 2: Figure S2). At day 2,
SEB strongly stimulated the PBMC, and IL-17 (the lower
secreted cytokine) measurement seemed to be the most
variable (24 to 66 pg/ml for patient A and 43 to 135 pg/
ml for patient B). HIV-specific stimulation induced very
low concentrations of IL-5 and IL-17, but the LP mix re-
sulted, in samples from patient A, in an IFNγ concentration
from 2,932 to 12,091 pg/ml and a Perforin concentration of
3,403 to 4,511 pg/ml. As expected, intraclass correlation
coefficients (ICCs) for HIV-stimulated samples for the
11-day stimulations were low (Table 2) whereas good
ICCs (>0.8) were observed with the 2-day cultures for
IFNγ (using either FI or concentrations) and Perforin
(using concentration in range only). We excluded extrapo-
lated concentration values, i.e., below or above the limits
of quantification (LOQ) and corresponding fluorescent
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Table 1 Description of Luminex kits
Supplier Kit name Type of beads Number of analytes Analytes Part of the study
BIIR + Biolegend - Polystyrene 4 IFNγ, IL-5, IL-17 + Perforin Reproducibility
Millipore Milliplex MAP Human Cytokine (#SPR137) Magnetic 11 IL-17, IL-21, IP-10, IFNγ, IL-10, IL-13, IL-1β, IL-2, IL-5, IL-6, TNFα Kinetics of cytokine production +
Quantity of stimulated PBMC
Millipore Milliplex MAP Human Cytokine (#SPR171) Polystyrene 10 IL-17, IL-21, IFNγ, IL-10, IL-13, IL-1β, IL-2, IL-5, IL-6, TNFα Kinetics of cytokine production +
Quantity of stimulated PBMC
Millipore Milliplex MAP Human Th17 Magnetic 10 IL-17A, IL-22, IFNγ, IL-10, IL-13, IL-1β, IL-2, IL-5, IL-6, TNFα Kinetics of cytokine production +
Quantity of stimulated PBMC
Ozyme Procarta Immunoassays kit (Affymetrix) Magnetic 16 GM-CSF, IFNγ, IL-10, IL-12p40, IL-13, IL-17A, IL-1β, IL-2, IL-22,
IL-5, IL-6, IP-10, MCP-1, MIP-1α, MIP-1β, TNFα
Comparison of commercial
Luminex Kits
Millipore Milliplex MAP Human Cytokine
(#SPR158) + Milliplex MAP Human
Cytokine/Chemokine
Magnetic 15 + 1 GM-CSF, IFNγ, IL-10, IL-13, IL-17A, IL-1β, IL-2, IL-22, IL-5, IL-6,
IP-10, MCP-1, MIP-1α, MIP-1β, TNFα + IL-12p40
Comparison of commercial
Luminex Kits
Bio-Rad Bio-plex Pro assays + Bio-Plex Pro Human
Th17 Cytokine assays
Magnetic 28 + 1 IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70,
IL-13, IL-15, IL-17A, Eotaxin, Basic FGF, G-CSF, GM-CSF, IFNγ,
IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNFα, VEGF,
and IL-12p40 + IL-22
Comparison of commercial
Luminex Kits
Millipore Milliplex MAP Human Th17 Magnetic 15 GM-CSF, IFNγ, IL-10, IL-17 F, IL-13, IL-17A, IL-1β, IL-2, IL-22, IL-9,














intensity (FI). Nevertheless, even excluding extrapolated
values, ICCs were not in all cases acceptable. For IL-5, the
agreement was too low (ICC < 0.6).
Kinetics of cytokine production
We performed kinetic studies over 7 days with samples
from two healthy donors to determine optimal culture
duration for quantification of weakly secreted cytokines
in stimulated-PBMC supernatants. First, we found that
the culture duration (without rIL-2 supplemented medium)
should not be longer than 6 days to maintain cell via-
bility above 70 % using non-stimulated or tuberculin
purified protein derivative (PPD)-stimulated PBMC
(Additional file 3).
T cell subsets can be characterized according to their
cytokine secretion profile. We focused on four cytokines:
the T-helper (Th)1 cytokines IFNγ and IL-2, the Th2 cyto-
kine IL-5, and the Th17 cytokine IL-17. The optimal cul-
ture duration was defined as that giving the highest
specific concentration (i.e. the largest positive difference
between stimulated and non-stimulated cells). The specific
concentration of IL-2 was maximal after two days of
stimulation whereas the specific concentration peaks for
IFNγ, IL-5 and IL-17 were on day 5 (Fig. 1). These find-
ings suggested that different time points (here day 2 and
day 5) are required for optimal quantifications of different
cytokines in supernatants from antigen-stimulated PBMC.
Number of stimulated PBMC
The quantity of PBMC available in clinical trials and the
numbers of specific cells are often small, so we com-
pared the use of 0.5 and 1.0 million cells per well: PBMC
from two healthy donors were stimulated with PPD and
assayed for the same four cytokines at their optimal time
point (Fig. 2). The concentration of IL-2 was slightly
lower after the stimulation of 0.5 million of PBMC per
well than 1.0 million of PBMC/well (29 vs. 49 pg/ml)
without any difference in the background (4 pg/ml). The
concentration of IFNγ was also slightly lower with 0.5
million than 1.0 million stimulated PBMCs (942 vs.
1,596 pg/ml), but a similar relative difference was ob-
served for the background (49 vs.112 pg/ml). There
was no significant difference in IL-5 concentrations be-
tween the two densities of PBMC. The concentration of
IL-17 following PPD stimulation was similar at the two
densities of PBMC but the background was significantly
lower at 0.5 million PBMCs per well (3 vs. 17 pg/ml).
Thus, the stimulation of PBMC at 0.5 and 1.0 million
per well resulted in relatively similar levels of specific
cytokine secretion (i.e. background subtracted).
Comparison of three commercial Luminex kits
Next, we compared Luminex kits supplied by different
manufacturers (Millipore, Ozyme and Bio-Rad). We first
analysed mean % CV from standard and samples coming
from polystyrene bead based 10-plex and magnetic bead
based 15-plex kits and found that they were lower with
magnetic beads (3.1 and 15.5, respectively) compared to
polystyrene ones (5.3 and 25.1, respectively), thus confirm-
ing the better precision of magnetic kits as previously de-
scribed [19]. In the next experiments, only Luminex kits
using magnetic beads were selected and analytes were
quantified at their optimal time point previously defined.
We first compared vendor-reported (theoretical) work-
ing range (lower limit of quantification (LLOQ) and upper
limit of quantification (ULOQ)) and experimental working
range for each kit. The working range was defined as that
for which the observed concentration was between 70 %
and 130 % of expected concentration using the five par-
ameter log-logistic (5PL) standard curve. The 16 cytokines
common to the three kits were studied and the results are
summarized in Table 3. A sensitivity lower than that re-
ported by the vendor was observed for some analytes for
all kits. The LLOQ was particularly discordant with
Ozyme and Bio-Rad kits for GM-CSF and especially with
the Bio-Rad kit for IL-12p40 (302.6 pg/ml instead of
Table 2 Intraclass correlation coefficients (ICCs) across HIV-stimulated samples
Cytokine FI Conca (pg/ml) Conc in range (pg/ml)
Culture duration Samples (n) Total meas. (n) ICC Samples (n) Total meas. (n) ICC Samples (n) Total meas. (n) ICC
IFNγ 11d 16 114 .69 16 107 .11 16 81 .51
Perforin 11d 16 91 .66 16 71 .17 16 61 .72
IL-5 11d 16 114 .36 16 106 .25 16 99 .23
IL-17 11d 16 114 .02 16 69 .02 16 28 .19
IFNγ 2d 17 135 .93 17 129 .88 17 122 .81
Perforin 2d 17 111 .16 17 97 NA 17 95 .88
IL-5 2d 17 135 .58 17 91 .55 17 86 .53
IL-17 2d 17 135 .43 17 37 .29 1 1 -
ICCs were calculated across 9 replicate cultures. The combination ‘donor x stimulation’ was treated as one sample. d day, Conc concentration, meas measurement.
ICCs > 0.8 are indicated in bold
aincluding extrapolated values, NA: G matrix ‘not positive definite’
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15.5 pg/ml, a three dilution difference). Ozyme and Bio-
Rad kits also showed a narrower standard spectrum than
expected: the observed ULOQ diverged by one or two di-
lutions from the theoretical value for many cytokines.
Overall, we obtained a better working range with Millipore
than Ozyme and Bio-Rad kits.
We then used intra-assay coefficients of variation (CVs)
to compare the precision of the three kits with standards
and samples. All kits performed well for standard intra-
assay precision: the mean of standard intra-plate CVs
for the 16 common cytokines was below 8 % for all kits
(Additional file 4: Figure S3). As this work was initially
performed to select the best Luminex kit for a TB/HIV
study, PBMC from two healthy donors, one HIV-1-
positive patient and one tuberculosis (TB)-positive patient
were cultured in triplicate for 2 and 5 days without anti-
gen (NS) or with PPD, early secreted antigenic target
6 kDa protein (ESAT-6) or SEB. The supernatant of each
culture well was considered to be one sample for Luminex
analysis. Not all the cytokines were included in the final
analysis because their values were above the ULOQ
(MCP-1, MIP-1α, MIP-1β and IL-6) or below the LLOQ
(IL-12p40). Eleven common cytokines were thus analyzed:
IP-10, IL-10, IL-1β and IL-2 after 2-day culture and IL-5,
GM-CSF, IFNγ, IL-17A, IL-13, IL-22, and TNFα after
5-day culture. CVs of three culture replicates for these
11 cytokines were plotted against the mean concentration
for NS, PPD, SEB and ESAT-6 stimulations. A charac-
teristic non-linear relationship was observed for all kits
(Additional file 5: Figure S4): the CV rose substantially
as the mean value approached zero.
Figure 3 shows %CVs obtained for each kit according
to culture conditions — NS, PPD- and SEB-stimulated
PBMC — highlighting the generally accepted 25 % cutoff
value for biomarker assay precision [22]. For SEB stimu-
lations, the overall mean pooled CV for all donors and
all cytokines (calculated from triplicates per cytokine
and per patient) was between 1 and 18 %. For PPD stim-
ulations, the values were 17.2 % for Bio-Rad, 19.4 % for
Millipore and 26.7 % for Ozyme; only the IL-5 CV was
above the 25 % threshold with the Bio-Rad kit in con-
trast to Millipore and Ozyme kits which showed CV
>25 % for IL-5, IL-13 and IL-17A. Applying a 30 % CV
threshold like the study by Defawe and colleagues [20],
the Millipore kit gave acceptable %CVs for IL-13. The
mean pooled CV was even higher for NS samples:
23.4 % for Ozyme, 25.8 % for Bio-Rad and 29.5 % for
Millipore.
Fig. 1 Kinetics of cytokine production. Milliplex kits from Millipore (see Material and Methods for details) were used to perform kinetic experiments
with PBMC from two healthy donors stimulated for 1, 2 or 5 days with PPD (1 μg/ml) and SEB (10 ng/ml) as positive control. Non-stimulated (NS) PBMC
were used as negative control. Results obtained for samples from donor 1 (IL-2 and IL-17) and donor 2 (IFNγ and IL-5) are shown. NS and PPD values
correspond to the left y axis and SEB values to the right y axis
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Next, we analyzed cytokine concentrations in the
supernatant from TB-infected stimulated PBMC. The
kits yielded different cytokine concentrations with qual-
ity control samples (QCs) from Millipore and these ex-
periments also revealed some cross-reactivities for the
Ozyme kit: it detected IL-22 at a high concentration in
the Millipore QCs which do not contain this cytokine
(Additional file 6). Although the kits gave results that
were generally compatible, there were discrepancies be-
tween them for particular cytokines (Fig. 4a). Another
approach to measuring cytokine production is the use of
a stimulation index (SI), calculated as a ratio between
mean antigen-stimulated PBMC concentration and mean
non-stimulated PBMC concentration. Like Defawe and
colleagues [20], we used a SI threshold of 3 for positivity
and observed that the kits tested gave divergent results for
IL-1β (Fig. 4b). Although no discrepancy between the kits
for positive or negative SI was observed for the other cyto-
kines, some SIs differed by 10 to 100 between kits. Thus,
our study showed variability in the measurement of cyto-
kine production (either with absolute concentration or SI)
in supernatants from antigen-stimulated PBMC with
luminex kits coming from different manufacturers.
Internal QC for Luminex study
For the last experiment, we used the Millipore kit be-
cause: 1) its working range and sensitivity were better
than the two other kits tested, 2) %CVs were as good as
the other kits, 3) no cross-reactivity was observed, 4) it
was the only kit with QCs provided, and 5) it contains
most analytes that we were interested in.
A “home-made” internal control (culture supernatant
from SEB-stimulated PBMC) was used in addition to
the two Millipore QCs (high and low concentration) to
evaluate intra- and inter-assay precision and thus to
check the reproducibility of the assay. This internal
control was used to determine variations observed for a
control sample prepared and stored under the same
conditions as our study samples. Intra- and inter-assay
%CVs for the internal control assayed in duplicate are
reported in Fig. 5 and Table 4, respectively, for 13 of
the 15 cytokines (IL-23 and IL-1β %CVs were not cal-
culated for the internal control due to concentration
values < LLOQ and >ULOQ, respectively). Low intra-
assay variability was observed both with the internal
control and Millipore QCs. Mean CVs for each cytokine
were <13 % for the “home-made” internal control (Fig. 5)
Fig. 2 Optimization of cell concentration. Milliplex kits from Millipore (see Material and Methods) were used to perform cell concentration
optimization experiments using 0.5 or 1.0 million Non-Stimulated (NS) or PPD-Stimulated PBMC from two healthy donors cultured in triplicate for
2 or 5 days. Results obtained with samples from donor 1 (IL-2 and IL-17) and donor 2 (IFNγ and IL-5) are shown at the optimal time point defined
for each cytokine. Mean cytokine concentrations are represented by black lines
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and <7 % for Millipore QCs (Additional file 7). Only two
of the 169 calculated intra-assay CVs for the internal
control were above the 25 % threshold. The inter-assay
variability was also low. The CV was <18 % for each
cytokine concentration in the internal control (Table 4),
and <14 % in the Millipore QCs (Additional file 7).
Thus, the Millipore Milliplex kits demonstrated a good
precision and reproducibility in our hands.
Discussion
The Luminex platform is widely used to study immune
responses but only few studies evaluated its reproducibility
and/or compared kits from different suppliers using super-
natants from stimulated PBMC [18–20]. This work was
designed to evaluate reproducibility of cytokine quantifica-
tion by Luminex assay in supernatants from antigen-
stimulated PBMC and to improve this quantification by
optimization of the culture protocol and eventually the
choice a particular commercial kit. We used cryopreserved
PBMC because such samples are typical of those used in
clinical trials. Moreover, it has been shown that using vali-
dated standard operating procedures (SOPs) for isolation,
cryopreservation and thawing of PBMC, CD4+ and CD8+
cells maintain full functionality in cytokine enzyme-linked
Table 3 Working range and sensitivities
Analyte Ozyme Millipore Bio-rad
theoretical experimental theoretical experimental theoretical experimental
LLOQ ULOQ LLOQ ULOQ LLOQ ULOQ LLOQ ULOQ LLOQ ULOQ LLOQ ULOQ
IL-17A 2.92 47900 2.90 12124a 9.60 30000 1.91 29561 1.78 29157 1.73 24822
IP-10 1.35 22100 1.10 5328a 1.60 5000 7.75a 4999 3.50 57400 3.12 52465
MCP-1 2.95 48400 2.60 12076a 1.60 5000 8.29a 5034 1.52 24920 1.64 24492
MIP-1α 0.52 8550 0.52 534b 1.60 5000 8.33a 5455 1.20 19707 1.21 3630a
MIP-1β 6.56 107500 24.58a 108640 1.60 5000 7.42a 4979 0.85 13960 1.03 10114
GM-CSF 4.29 70300 59.10b 70495 50.00 130000 10.00 117900 1.24 20314 16.27b 20993
IFNγ 0.20 3200 0.20 2323 8.00 25000 1.81 24966 2.13 34920 7.50a 34918
IL-10 0.34 5550 0.27 5424 2.40 7500 0.40 7502 1.59 26094 1.56 6551a
IL-13 2.89 47400 2.68 48745 6.40 20000 1.37 20019 2.40 39338 2.43 9065a
IL-22 13.47 220700 13.56 13752b 24.00 75000 4.66 75275 4.19 68313 4.22 17087a
IL-1β 0.71 11700 0.71 10791 4.80 15000 1.00 15029 1.90 31130 1.91 6893a
IL-2 0.40 6550 1.25a 7119 9.60 30000 1.92 30166 0.84 13690 3.09a 14356
IL-5 0.84 13800 3.28a 16674 5.60 17500 1.20 17052 2.34 38356 2.35 2392b
IL-6 0.92 15000 0.83 14549 3.20 10000 0.53 10233 1.54 25160 1.56 23428
TNFα 2.05 33600 1.87 2099b 3.20 10000 0.68 9999 6.54 107172 6.78 26507a
IL-12p40 3.34 54700 3.28 3092b 3.20 10000 15.46a 9965 4.72 77321 302.60c 77346
Differences between theoretical and experimental limits of quantifications (LOQs) expressed in pg/ml are highlighted with a, b, and c for 1-dilution, 2-dilution and
3-dilution differences from theoretical LOQ, respectively
Fig. 3 Intra-assay precision of samples. %CV of the concentrations (mean CVs for four donors calculated using triplicate cultures for each
cytokine) as determined with Luminex magnetic kits from Ozyme, Millipore, and Bio-Rad for the 11 common analyzed cytokines. Left panel:
Non-stimulated PBMC; middle panel: PPD-stimulated PBMC; right panel: SEB-stimulated PBMC. Mean CVs calculated for all donors and all
cytokines are represented by red lines
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immunospot (ELISpot) assays [23]. We first tested two dif-
ferent stimulation protocols: a two-round stimulation (i.e.
cytokine measurement on day 11, after a first stimulation
on day 0 and a re-stimulation on day 9) in the presence of
rIL-2 supplemented medium, and a one-round stimulation
for 1 to 7 days without rIL-2 supplemented medium. The
two-round stimulation protocol induced a lot of variabil-
ity. However, this type of protocol could be valuable to in-
vestigate “on/off” signals if no precise quantification of
secreted cytokines is required. We also observed some
variability, although to a lesser extent, with the 48 h stimu-
lation protocol. Like ELISpot assay, the observed variabil-
ity with the Luminex assay, which is inherent to cell
culture, probably resulted in part from variations in count-
ing and pipetting, and low antigen-specific cell frequency
[24]. One way to minimize this variability is to perform
multi-well stimulations and to pool supernatants before
assaying them by the Luminex platform.
Another factor to take into consideration for cytokine
quantifications in stimulated-PBMC supernatants is the
cell viability. Defawe et al. claimed that a high cell viabil-
ity limited the potential effect of dead cells on cytokine
a
b
Fig. 4 Cytokine profiles in TB-infected patient. Cytokine production by PPD- and ESAT-6-stimulated PBMC from a TB-infected donor was measured
with kits from Millipore, Ozyme and Bio-Rad. a Specific cytokine Concentrations (background values subtracted). b Stimulation Index (ratio between
stimulated and background concentration values). The value for IL-22 from non-stimulated PBMC given by the Millipore kit was inferior to the range of
the standard curve and was therefore imputed by the lowest extrapolated value for this cytokine (3.1 pg/ml). The IL-17A concentration with ESAT-6
stimulation was a null value for all kits, so SI could not be calculated. The positive threshold for the SI was set at 3 (black line)
Fig. 5 Intra-assay variability of internal control. %CV concentration for
each of the 13 plates calculated using internal control duplicates for the
selected 15-plex Millipore magnetic kit (see Material and Methods). Mean
%CVs are represented by red lines. IL-23 and IL-1β %CVs were not
calculated due to concentration values < LLOQ and >ULOQ, respectively
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content measured by Luminex [20]. However, we ob-
served that having cell viability above 80 % on the day of
stimulation (D0) was not sufficient to ensure low cell
mortality during the culture. Indeed, a dose of 100 ng/ml
SEB (10-fold lower than that used in the study by Defawe
and colleagues) killed near 50 % of PBMC after 5 days of
culture (data not shown). Consequently, the antigen dose
needs to be adapted.
Our results suggest that two different time-points are
required for optimal quantifications of different cyto-
kines (IFNγ, IL-2, IL-5 and IL-17) in supernatants from
antigen-stimulated PBMC. This is consistent with pub-
lished results. Indeed, differences in the kinetics of IFNγ
and IL-2 production have already been observed in
whole blood cell cultures [25]. The duration of in vitro
stimulation of PBMC with recall antigens determines the
subset distribution of IFNγ-producing cells, and 4 or
5 days of stimulation are necessary to have a predominance
of IFNγ-secreting T cells [26]. Lagrelius and colleagues re-
ported that 3 and 7 days are the most suitable periods for
stimulation to measure various cytokine levels in whole
blood supernatant [27]. Furthermore, our results validating
the use of 0.5 million PBMC per well are in agreement with
those obtained by others with cytomegalovirus (CMV)
stimulation [20].
After setting up our protocol for cytokine measure-
ments in supernatants coming from antigen-stimulated
PBMC, we compared results obtained with Luminex
magnetic kits coming from three different manufacturers.
We observed a lower sensitivity than that reported by the
vendor for some analytes for all kits but overall, we ob-
tained a better working range with Millipore than Ozyme
and Bio-Rad kits. Also, Djoba Siawaya and colleagues re-
ported a comparison between commercial Luminex cyto-
kine kits using whole blood supernatant and concluded
that the LINCO (now Millipore) kit was the most sensitive
for measuring concentrations of numerous recombinant
cytokines in samples that had been spiked with serial
dilutions of the standards provided by the manufacturer
[17]. Consistent with our results, Belabani and colleagues
showed that a Bio-Rad magnetic Luminex kit was not as
sensitive as suggested by the manufacturer for some cyto-
kines [28]. In their condensed performance-validation
strategy for multiplex detection kits used in studies of
human clinical samples recently published, these authors
proposed a complete validation of Luminex assays.
Among the critical points, we would also recommend 1)
extending the standard curve to include lower values to
check the working range and true sensitivity; 2) including
LLOQs and ULOQs as validation samples to validate their
concentration; 3) excluding values below the LLOQ or
using specific statistical analyses that takes into account
left-censoring [29]; 4) diluting and reanalyzing all samples
with a concentration above the ULOQ; and 5) fixing the
thresholds of %CV and %Recovery at 25 % (30 % for
LLOQs) as acceptance criteria for samples, as defined by
Lee and colleagues [22].
We then compared the precision of the three kits with
standards and samples. It is important to note that we
used here triplicate cultures in our Luminex assays (and
not supernatant pooled from several culture wells) to es-
timate the variability cytokine assays results, and this
could explain at least in part the high variability ob-
served. As observed for ELISpot [23], but also tetramer
Table 4 Inter-assay variability of internal control
Plates IL-17F GM-CSF IFNγ IL-10 CCL20/MIP3α IL-13 IL-17A IL-22 IL-9 IL-2 IL-5 IL-27 TNFα
1 2091.2 7423.2 5300.1 81.4 9523.6 2248.3 74.0 45.4 225.6 89.8 191.9 808.9 3424.9
2 2059.3 6734.8 6833.8 82.0 9009.3 2537.1 90.9 65.0 256.9 107.0 224.2 1081.6 4126.7
3 1963.3 6811.0 5144.7 74.7 5706.4 2268.3 82.2 46.3 216.1 90.9 214.7 786.4 3571.6
4 2215.3 8326.4 5348.7 78.4 8241.1 2412.0 83.1 53.8 231.1 104.7 205.1 1308.3 3953.4
5 1998.1 6735.9 5506.4 61.1 8311.7 2064.6 72.1 48.5 195.9 89.2 172.9 1026.8 3385.1
6 2238.5 7407.3 6040.5 85.1 6113.7 2259.9 89.1 61.5 263.3 84.2 218.3 1093.6 4302.2
7 2473.7 8788.0 5809.2 71.3 8211.6 2560.0 88.3 47.0 278.8 98.5 243.6 1102.3 4128.4
8 2425.1 7440.4 5180.8 81.6 10147.7 2429.5 84.7 50.8 254.4 105.9 214.3 1190.2 4310.1
9 1945.9 6719.6 4545.8 68.4 8901.7 2384.8 82.4 53.3 198.0 95.8 221.2 1175.7 4241.0
10 2165.8 7817.6 7062.7 88.5 10767.6 2729.8 87.8 50.3 296.4 110.3 241.2 1070.5 5285.1
11 2185.4 6660.9 4907.7 68.6 8756.7 2387.7 70.6 39.6 180.1 91.9 170.5 914.5 3409.2
12 2151.4 7223.0 5796.1 65.0 8429.9 2304.6 71.1 42.6 224.8 86.8 195.3 1088.9 4515.4
13 2231.2 7964.7 5324.4 78.5 7028.9 2618.0 87.1 51.7 237.8 113.9 230.2 1249.2 4951.5
%CV 7.4 9.2 12.8 11.0 17.2 7.4 9.0 14.0 14.4 10.0 11.0 14.6 14.3
Mean concentration values of duplicate Internal Controls (pg/ml) and %CVs of mean concentration calculated using the 13 inter-plates internal control mean
concentration values for the selected 15-plex Millipore magnetic kit (see Material and Methods section for detailed analytes). IL-23 and IL-1β %CVs were not
calculated due to concentration values < LLOQ and > ULOQ, respectively
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assays and cytokine flow cytometry [24], the relationship
between CV and mean response level is not linear. The
stability of the CV is poor at very low mean values, and
antigen-specific assays are often used to analyze data in
a range where CV is non-linear. Consequently, Maecker
and colleagues suggested using Standard Deviation (SD),
which may be related linearly to the response mean, to
compare the precision of different assays [24]. However,
we did not find a clear linear correlation between SD
and mean concentration (Additional file 8), and there-
fore we used %CV to compare precision of the different
kits. Our results confirmed that the lower the secretion,
the higher the %CV and that IL-5, IL-13 and IL-17A
were difficult to quantify accurately even at the optimal
time point, whatever the kit used. Another group has
compared Luminex kits for the measurement of cyto-
kines in supernatants collected from antigen-stimulated
PBMC: they report good intra-plate but poor inter-plate
precision of the Bio-Rad 17-plex kit [18] and found that
the Millipore magnetic kit gave the most reproducible
results [19]. In our hands, the good precision of Milli-
pore kits was confirmed, as mean % CV of standards
and samples from 2 different kits (10-plex versus 15-plex
magnetic beads based kits) were similar.
We also used a “home-made” internal control to
evaluate precision and reproducibility of Milliplex kits as
suggested by De Jager and colleagues in their work with
serum, plasma and whole blood culture supernatant to
define the prerequisites for cytokine measurements in
clinical trials with multiplex immunoassays [30]. We
showed that the Millipore Milliplex kits demonstrated a
good precision and reproducibility in our hands. Similarly,
in their study of optimization and qualification of a multi-
plex bead array to assess cytokine and chemokine produc-
tion by vaccine-specific cells, Defawe and colleagues found
CVs for the intra-assay and inter-day variability below
30 % for all but one analyte with a Millipore kit [20].
Our study showed variability in the measurement of
absolute cytokine concentration in supernatants from
antigen-stimulated PBMC with Luminex kits coming
from different manufacturers. A previous study showing
that a Bio-Rad kit was more sensitive than an Invitrogen
kit revealed the potential for differences in absolute
cytokine concentration reported by these two kits [18].
Other studies also showed variability in the measurement
of absolute cytokine concentrations in serum or plasma
[13–16]. Possibly, the different capture and detection anti-
bodies are the major causes of the differences in perform-
ance of multiplex kits from different manufacturers as
well as the heterogeneity in analytes within each kit. Also,
differences between the purified recombinant proteins
used to generate the standard curves, and between assay
buffers supplied by the manufacturers are likely to con-
tribute to the divergent results, as well as cross-reactivities
observed with the Ozyme kit. Thus, the main criterion to
select a manufacturer should be the availability of the
panel of analytes that needs to be quantified and mixing
data coming from different kits for analyses should be
banned.
To determine positivity of samples, Defawe and col-
leagues used an empirical method based on their ex-
perience using the assay and they aimed to control the
false positive rate below 3 % [20]. The first criterion
was “minimum analyte concentration over background”
determined for each analyte and the second criterion
was “minimum fold increase over background concentra-
tion”. The minimum fold increase over background con-
centration criterion was set as three-fold for all analytes.
We used the same second criterion in this study to cal-
culate the SI, but the definition used for the first criter-
ion is debatable because there is no consensus formula
to determine the minimum analyte concentration over
background.
Conclusions
Here, we demonstrate that a protocol with a single round
of stimulation but with two time points (day-2 and day-5)
gave the optimal quantifications for different cytokines
using 0.5 million PBMC per well, a cell quantity that gave
the same level of specific cytokine secretion as 1.0 million.
Millipore kits appear to be slightly more sensitive than
those from Bio-Rad and Ozyme. However, we conclude
that the panel of analytes that need to be quantified should
be the main determinant of kit selection and that the same
kit must be used throughout any given study. We also
think that it is important to use the same batch number
throughout the study to allow results to be compared be-
tween plates. To ensure the validity of the results, we also
recommend the use of an internal control. Using this type
of sample, we demonstrated that a 15-plex magnetic Milli-
plex kit displayed good precision and reproducibility.
Moreover, our study suggests that particular attention
should be paid to cell viability during cell culture to ensure
that high cell mortality does not perturb the nature of cy-
tokines secreted. Finally, to limit the variability inherent to
cell culture, we suggest the use of supernatant pooled
from at least three culture replicates to avoid large varia-
tions in the cytokine concentrations observed. In view of
the cost of the technique and the good reproducibility of
the results obtained with Millipore QC and with our in-
ternal control (intra- and inter-plate %CVs), it is unclear
whether supernatant replicates are beneficial if standard
curves are performed in duplicate and are extended to
include lower levels so as to confirm the working range.
In summary, our findings should help optimize assays
for quantifying immune mediators during the course of
disease or infection, or in response to vaccine or therapy.
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Methods
Blood sample processing
Whole blood specimens were collected from two healthy
controls (from the Etablissement Français du Sang, Créteil,
France), seven HIV-seropositive patients (from the Mondor
Hospital cohort, Créteil, France) and one TB-infected
patient (from St-Louis Hospital, Paris, France).. PBMC
were isolated using LSM 1077 density gradient media
(PAA), washed with PBS without calcium or magnesium
(Life Technologies), frozen in fetal calf serum (FCS, PAA)
containing 10 % DMSO (Sigma) and stored in liquid nitro-
gen. For each experiment, about 12-18x106 PBMC (one
cryovial) were thawed in R-20 (RPMI 1640 + glutamax
containing 100 U/ml penicillin and 0.1 mg/ml strepto-
mycin (Life Technologies) and 20 % FCS) medium and
rested for 3 h at 37 °C, under 5 % CO2 in R-10HS
(RPMI 1640 + glutamax containing 100U/ml penicillin
and 0.1 mg/ml streptomycin and 10 % AB Human
serum (HS, PAA)) medium. A minimal cell viability of
75 % as measured with an Auto 2000 cellometer (Nex-
celom) after resting was required for use.
PBMC stimulations
Two different protocols were used for PBMC stimulations.
For the first one (2-step stimulation), PBMC (1×106) were
stimulated for 2 days at 37 °C, under 5 % CO2 in a final
volume of 300 μl R-10HS in 96 deep well plates (Greiner)
with (i) 2 μg/ml of LIPO-5 vaccine composed of the clade
B LAI HIV-1 Nef 66–97, Nef 116–145, Gag 17–35, Gag
253–284 and Pol 325–355 regions, coupled to a lipid tail
[21]; (ii) 2 μg/ml of a mix of five long HIV-1 peptides (LP
mix, NeoMPS) corresponding to the sequences included
in the LIPO-5 vaccine without the lipid tail; (iii) 2 μg/ml
of a pool of 36 HIV-1 15-mer peptides (NeoMPS) overlap-
ping by 11 amino acids and spanning Nef, Gag and Pol se-
quences encoded by the LIPO-5 vaccine. Aliquots of
200 μl of supernatant were harvested on day 2, and 900 μl
of fresh R-10HS medium containing 100 IU/ml human
recombinant IL-2 (rIL-2, Miltenyi) was added. On days
4, 7 and 8, 500 μl of medium was replaced with fresh
R10-HS medium containing 100 IU/ml rIL-2. On day 9,
800 μl of supernatant was discarded, cells were transferred
in 96 V-bottom wells culture plates (Greiner), washed in
PBS, resuspended in R-10HS medium containing the same
concentrations of the corresponding antigens and incu-
bated for 2 days at 37 °C, under 5 % CO2 in a final volume
of 200 μl R-10HS. Positive and negative controls consisted
of PBMC cultured with 100 ng/ml of SEB (Sigma, only for
the two last days of stimulation) and PBMC cultured in R-
10HS alone (non-stimulated, NS), respectively. For the
second protocol of PBMC stimulation (1-step stimula-
tion), PBMC (0.5×106 or 1×106) were stimulated for 1 to
7 days at 37 °C, under 5 % CO2 in a final volume of 300 μl
R-10HS in 96 deep well plates (Greiner) with: (i) 2 μg/ml
of LIPO-5 vaccine [21]; (ii) 2 μg/ml of LP mix (NeoMPS);
(iii) 2 μg/ml of a pool of 36 HIV-1 15-mer peptides
(NeoMPS) overlapping by 11 amino acids; (iv) 1 μg/ml of
PPD (Statens Institute) and (v) 5 μg/ml of ESAT-6, a
Mycobacterium tuberculosis T-specific antigen (Statens In-
stitute). Positive and negative controls consisted of PBMC
cultured with 10 ng/ml of SEB (Sigma) and PBMC cul-
tured in R-10HS alone (non-stimulated, NS), respectively.
Supernatants were harvested at days 2/11 for the re-
stimulation (2-step) protocol and after various times of
culture for the 1-step protocol. They were then frozen
at -80 °C until assessment.
Cytokine and chemokine assays with Luminex kits
All Luminex kits used for this study are described in de-
tail in Table 1. Luminex reproducibility was evaluated
using a Luminex kit developed and shared by the Baylor
Institute for Immunology Research (BIIR, Dallas, TX,
USA). This kit contained polystyrene beads from BIIR
and Biolegend and standards from Biolegend. We used
three Milliplex MAP kits from Millipore to optimize our
stimulation protocol: a 11-plex human cytokine magnetic
bead panel kit (#SPR137), a 10-plex human cytokine panel
kit (#SPR171), and a 10-plex human Th17 magnetic bead
panel. We compared the following commercial kits: one
16-plex magnetic Procarta Immunoassays kit (Affymetrix)
from Ozyme; one 15-plex Milliplex MAP human cytokine
magnetic bead panel kit (#SPR158) and one simplex
Milliplex MAP human cytokine/chemokine magnetic
bead panel, both from Millipore; one Bio-Plex Pro assays
magnetic kit and one Bio-Plex Pro human Th17 cytokine
assays kit, both from Bio-Rad. A 15-plex Milliplex MAP
human Th17 magnetic bead panel (Millipore, Saint-
Quentin en Yvelines, France) was selected for the last part
of our study; precision was evaluated using intra- and
inter-variability with Millipore QCs and an internal con-
trol (pool of SEB-stimulated PBMC supernatants from the
two healthy donors). All samples were acquired on a
Bioplex-200 instrument (Bio-Rad, Marnes-la-Coquette,
France). All experiments were performed by the same op-
erator according to the manufacturers’ instructions.
Statistical analysis
The concentration of each analyte was obtained by inter-
polating FI to a dilution standard curve over at least 7
dilution points supplied with the kit and calculated using
a 5PL curve by the Bio-Plex Manager 5.0 software (Bio-
Rad). ICCs were used to assess reproducibility. The ICC
is a measure of reliability, assessing the proportion of
overall variability that is explained by the variability due
to differences between samples [31]. Generally, reliability
is considered to be good if the point estimate of the
intra-class correlation coefficients is at least >0.7, and
ideally > 0.8. ICCs were derived from linear mixed effects
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models with a random effect for the intercept. The ICC
was defined as the ratio of variance between superna-
tants to total variance. The assumption of Gaussian dis-
tributions of the residuals was verified. CVs (standard
deviation over mean) were used to assess precision. A SI
(calculated as a ratio between stimulated-cell super-
natant concentration values and background concentra-
tion values) was used to reveal differences between the
kits. All graphs were prepared using Microsoft Excel and
GraphPad Prism. SAS (version 9.2, SAS Institute, Cary,
North Carolina, USA) and GraphPad Prism (version 6.0,
GraphPad Software, La Jolla, California, USA) were used
for statistical analyses.
Additional files
Additional file 1: Figure S1. Intra-laboratory reproducibility with 11-day
cultures. Results after 11-day cultures of PBMC from two representative
HIV-infected patients (A and B, CD4 count > 500 mm3, HIV-1 RNA < 50
copies/ml) stimulated with LIPO-5 vaccine, a mix of 5 long HIV-1 peptides
(LP mix), a pool of 15-mers HIV-1 peptides, or SEB as a positive control.
IFNγ, IL-5, and IL-17 polystyrene beads from Baylor Institute for Immunology
Research, Texas, USA and Perforin beads from Biolegend were used. Cultures
were performed on three different days (black, green, blue) in triplicate for
each day with 1.0 million PBMC per well. (PDF 110 kb)
Additional file 2: Figure S2. Intra-laboratory reproducibility with 2-day
cultures. Results after 2-day cultures of PBMC from two representative
HIV-infected patients (A and B, CD4 count > 500 mm3, HIV-1 RNA < 50
copies/ml) stimulated with LIPO-5 vaccine, a mix of 5 long HIV-1 peptides
(LP mix), a pool of 15-mers HIV-1 peptides, or SEB as a positive control. IFNγ,
IL-5, and IL-17 polystyrene beads from Baylor Institute for Immunology
Research, Texas, USA and Perforin beads from Biolegend were used. Cultures
were performed on three different days (black, green, blue) in triplicate for
each day with 1.0 million PBMC per well. (PDF 110 kb)
Additional file 3: PBMC viability over 7 days of culture. PBMC Viability
(%) from one healthy donor for two different experiments was
determined by Acridine Orange/Propidium iodide (AOPI) staining with
Auto 2000 cellometer (Nexcelom) with NS-, PPD (1 μg/ml)-, or SEB (10 or
100 ng/ml)-stimulated PBMC for 1 to 7 days. (PDF 184 kb)
Additional file 4: Figure S3. Intra-assay precision of standards. %CVs
concentration calculated using standard duplicates from Luminex
magnetic kits from Ozyme, Millipore and Bio-Rad for the 16 cytokines
common to all three kits. Mean %CVs for all cytokines are represented
by red lines. (PDF 27 kb)
Additional file 5: Figure S4. Non-linear relationship between %CV and
mean cytokine concentration. %CVs concentration (mean CVs for four
different donors and four conditions [NS, PPD, SEB and ESAT-6 stimulations]
calculated using culture triplicates for each of the 11 cytokines analyzed) plot-
ted against corresponding mean concentrations for Ozyme, Millipore and Bio-
Rad kits. (PDF 98 kb)
Additional file 6: IL-22 cross-reactivity with Ozyme kit. IL-22 concentration
(pg/ml) determined with the three different kits in Millipore QC that do not
contain this cytokine. (PDF 6 kb)
Additional file 7: Intra- and inter-assay precision for Millipore QCs. %CV
concentration for each of the 13 plates calculated using Millipore QCs
(QC1 = high and QC2 = low) duplicates for the selected 15-plex Millipore
magnetic kit (see Material and Methods). IL-23 and IL-1β %CVs were not
calculated due to concentration values < LLOQ and > ULOQ, respectively.
Mean concentration values of Millipore QCs (QC1 = high and QC2 = low)
duplicates (pg/ml) and %CVs of mean concentration calculated using the
13 inter-plates mean concentration values for the selected 15-plex Millipore
magnetic kit (see Material and Methods section for detailed analytes). IL-23
and IL-1β %CVs were not calculated due to concentration values < LLOQ
and > ULOQ, respectively. (PDF 252 kb)
Additional file 8: Absence of linear correlation between SD and mean
concentration values. SD calculated using culture triplicates for NS, PPD-
and SEB-stimulated PBMC from TB-infected patient plotted against IFNγ,
IL-5 and IL-17A corresponding mean concentration values for Ozyme,
Millipore and Bio-Rad kits. (PDF 14 kb)
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